Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 8:15:1363513.
doi: 10.3389/fneur.2024.1363513. eCollection 2024.

Online cognitive testing in Parkinson's disease: advantages and challenges

Sharon Binoy #  1   2   3 , Avigail Lithwick Algon #  2   3 , Yoad Ben Adiva  2   3 , Leila Montaser-Kouhsari  4 , William Saban  2   3
Affiliations
Review

Online cognitive testing in Parkinson's disease: advantages and challenges

Sharon Binoy et al. Front Neurol. .

Abstract

Parkinson's disease (PD) is primarily characterized by motor symptoms. Yet, many people with PD experience cognitive decline, which is often unnoticed by clinicians, although it may have a significant impact on quality of life. For over half a century, traditional in-person PD cognitive assessment lacked accessibility, scalability, and specificity due to its inherent limitations. In this review, we propose that novel methods of online cognitive assessment could potentially address these limitations. We first outline the challenges of traditional in-person cognitive testing in PD. We then summarize the existing literature on online cognitive testing in PD. Finally, we explore the advantages, but also the limitations, of three major processes involved in online PD cognitive testing: recruitment and sampling methods, measurement and participation, and disease monitoring and management. Taking the limitations into account, we aim to highlight the potential of online cognitive testing as a more accessible and efficient approach to cognitive testing in PD.

Keywords: Parkinson’s disease; basal ganglia; cognitive testing; early detection; online.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Kouli A, Torsney KM, Kuan W-L. Parkinson’s disease: etiology, neuropathology, and pathogenesis In: Whitman WB, Rainey F, editors. Parkinson’s disease: Pathogenesis and clinical aspects. Brisbane (AU): Codon Publications. (2018). - PubMed
    1. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. (2008) 79:368–76. doi: 10.1136/jnnp.2007.131045 - DOI - PubMed
    1. Aarsland D, Creese B, Politis M, Chaudhuri KR, ffytche DH, Weintraub D, et al. . Cognitive decline in Parkinson disease. Nat Rev Neurol. (2017) 13:217–31. doi: 10.1038/nrneurol.2017.27, PMID: - DOI - PMC - PubMed
    1. Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD. Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. (2019) 65:20–31. doi: 10.1016/j.parkreldis.2019.04.020, PMID: - DOI - PubMed
    1. Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, et al. . Detecting mild cognitive deficits in Parkinson’s disease: comparison of neuropsychological tests. Mov Disord. (2018) 33:1750–9. doi: 10.1002/mds.110, PMID: - DOI - PMC - PubMed

LinkOut - more resources